| Filed On | Filing |
|---|---|
| 05 Nov 2026 |
8-K: Results of Operations and Financial Condition
–Initiated the RECEPTIVE-CD1 Phase 2b clinical trial of SL-325 in Crohn’s disease; 12-week induction data expected in the first half of 2028 – |
| 11 Aug 2026 |
8-K: Results of Operations and Financial Condition
–Phase 1 clinical trial results for SL-325 demonstrated a favorable safety profile, a potentially best-in-mechanism immunogenicity profile, and durable DR3 blockade of TL1A binding, potentially enabling prolonged dosing intervals – |
| 11 Jun 2026 |
8-K: Entry into a Material Definitive Agreement
Pre-Funded Warrants to Purchase 7,870,624 Shares of Common Stock |
| 09 Jun 2026 |
8-K: Regulation FD Disclosure; Other Events
Potentially best-in-mechanism immunogenicity profile, with only 3.7% of participants developing antidrug antibodies |
| 02 Jun 2026 |
8-K: Departure/Election of Directors or Officers; Compensation; Submission of Matters to a Vote of Security Holders
(a) Successor to Prior Plan. This Plan is the successor to the Shattuck Labs, Inc. 2016 Stock Incentive Plan, as amended by Amendment No. 1 thereto (the “Prior Plan”). From and after 12:01 a.m. Central time on the Effective Date, no addi... |
| 07 May 2026 |
8-K: Results of Operations and Financial Condition
AUSTIN, TX and DURHAM, NC, May 7, 2026 – Shattuck Labs, Inc. (Shattuck or the Company) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of potential first-in-class monoclonal and bispecific DR3 blocking a... |
| 05 Mar 2026 |
8-K: Results of Operations and Financial Condition
–Phase 1 clinical trial of SL-325 ongoing, with data expected in the second quarter of 2026 – |
| 05 Feb 2026 |
8-K: Other Events
On February 5, 2026, the Board of Directors (the “Board”) of Shattuck Labs, Inc. (the “Company”) determined that the 2026 annual meeting of stockholders (the “Annual Meeting”) will be held on Thursday, May 28, 2026. All other relevant in... |
| 22 Jan 2026 |
8-K: Entry into a Material Definitive Agreement
Shattuck Labs, Inc., a Delaware corporation (the “Company”), confirms its agreement (this “Agreement”) with Leerink Partners LLC (the “Agent”), as follows: |
| 06 Nov 2025 |
8-K: Results of Operations and Financial Condition
–First participants dosed in Phase 1 clinical trial of SL-325 in healthy volunteers – |
| 26 Aug 2025 |
8-K: Departure/Election of Directors or Officers; Compensation; Regulation FD Disclosure
Aggregate net proceeds from private placement expected to fund SL-325 through multiple Phase 2 clinical trials, including in Inflammatory Bowel Disease (IBD) and potentially another autoimmune disease – |
| 14 Aug 2025 |
8-K: Results of Operations and Financial Condition
–Submitted Investigational New Drug (IND) application to evaluate SL-325 in a Phase 1 clinical trial in healthy volunteers; clearance expected in Q3 2025 – |
| 05 Aug 2025 |
8-K: Entry into a Material Definitive Agreement; Unregistered Sales of Equity Securities +1 more
This SECURITIES PURCHASE AGREEMENT (this “Agreement”) is dated as of August 4, 2025, by and among Shattuck Labs, Inc., a Delaware corporation (the “Company”), and each of the entities listed on Exhibit A attached to this Agreement (each,... |
| 15 Jul 2025 |
8-K: Submission of Matters to a Vote of Security Holders
On Thursday, July 10, 2025, Shattuck Labs, Inc. (the “Company”) held its 2025 Annual Meeting of Stockholders (the “Annual Meeting”). As of the close of business on May 14, 2025, the record date for the Annual Meeting, there were 47,903,2... |
| 01 May 2025 |
8-K: Results of Operations and Financial Condition
–Company advances SL-325 program with an IND filing expected in the third quarter of 2025 – |
| 27 Mar 2025 |
8-K: Results of Operations and Financial Condition
–Presented preclinical non-human primate (NHP) data at the 20th Congress of European Crohn’s and Colitis Organization in Inflammatory Bowel Diseases 2025 (ECCO) for SL-325, a potentially first-in-class blocking antibody to DR3, the recep... |
| 14 Nov 2024 |
8-K: Results of Operations and Financial Condition
–Announced development of SL-325, a first-in-class antagonist antibody to DR3, the receptor for TL1A; IND filing expected in Q3'2025 – |
| 01 Oct 2024 |
8-K: Termination of a Material Definitive Agreement; Costs Associated with Exit or Disposal Activities +1 more
Shattuck Labs Provides Company Update and Announces SL-325, a First-In-Class Death Receptor 3 (DR3) Antagonist Targeting the TL1A/DR3 Signaling Pathway |
| 01 Aug 2024 |
8-K: Results of Operations and Financial Condition
–Announced updated positive interim data from the Phase 1B dose-expansion clinical trial of SL-172154 in combination with Azacitidine (AZA) in frontline Higher-Risk Myelodysplastic Syndromes (HR-MDS) and TP53 mutant (TP53m) Acute Myeloid... |
| 14 Jun 2024 |
8-K: Regulation FD Disclosure
Shattuck Labs Announces Updated Positive Interim Data from the Phase 1B Dose Expansion Clinical Trial of SL-172154 in Combination with Azacitidine (AZA) in Frontline Higher-Risk Myelodysplastic Syndromes (HR-MDS) and TP53 mutant (TP53m) ... |
Loading...